Recombinant Human Cytochrome P450 2A6 (CYP2A6), partial

^{In
Stock}

中文名稱：

Recombinant Human Cytochrome P450 2A6(CYP2A6),partial
品名簡稱：

Recombinant Human CYP2A6 protein, partial
貨號：

CSB-EP006410HUe1
說明書：

MSDS Datasheet
規格：

￥2832
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

Greater than 85% as determined by SDS-PAGE.
生物活性：

Not Test
基因名：

CYP2A6
Uniprot No.：

P11509
別名：

(1,4-cineole 2-exo-monooxygenase)(CYPIIA6)(Coumarin 7-hydroxylase)(Cytochrome P450 IIA3)(Cytochrome P450(I)
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
來源：

E.coli
分子量：

53.5 kDa
表達區域：

29-494aa
氨基酸序列

SKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSNGERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSNVISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQLLQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFIGGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLNEKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGFATIPRNYTMSFLPR
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

Tag-Free
產品提供形式：

Liquid or Lyophilized powder Warning: in_array() expects parameter 2 to be array, null given in /www/web/cusabio_cn/public_html/caches/caches_template/default/content/show_product_protein.php on line 668
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
復溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
Datasheet & COA：

Please contact us to get it.

產品評價

靶點詳情

功能：

Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
基因功能參考文獻：
1. Results identified a significant association between CYP2A6 rs113288603 and hearing loss symptoms and confirm the role of tobacco smoking in age-related hearing loss mediated by CYP2A6. PMID: 28432340
2. genetic association studies in population in China: Data suggest that SNPs in CYP2C9 and CYP2A6 are associated with hepatotoxicity due to antiepileptic drug valproate in the population studied. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2A6 = cytochrome P450 family 2 subfamily A member 6) PMID: 28273397
3. Our results demonstrated the presence of functional variability in CYP2a6 activities resulting from amino acid substitutions caused by genetic polymorphisms. PMID: 27974382
4. Cynomolgus monkey CYP2A24, which shows 95% amino acid identity to human CYP2A6. PMID: 27625140
5. CYP2A6 rs60823196 and rs138978736 are possible risk factors for serious toxicity in Chinese gastric carcinoma patients treated with S-1 plus oxaliplatin chemotherapy. PMID: 28811232
6. Genetic polymorphisms in CYP2B6 and CYP2A6 explained a significant proportion of variability in EFV plasma concentration in HIV-infected children in a multi-ethnic outpatient clinic. PMID: 28886044
7. In a Mexican Mestizo population, rs1137115(A) and rs4105144(T) in CYP2A6 are associated with cigarette consumption PMID: 28734893
8. CYP2B6/CYP2A6 genotypes were associated with increased reported suicidality among AIDS patients who had been randomly assigned to receive efavirenz-containing regimens in clinical trials. Strength of association varied by race/ethnicity. PMID: 28931220
9. The CYP2A6 gene product plays a major role in the nicotine metabolism pathway, which influences nicotine intake. PMID: 27113016
10. CYP2A6 activity provides information on lung cancer risk that is not captured by smoking history. PMID: 28542511
11. CYP2A6*4 genetic polymorphisms may not strongly affect smoking behavior but may possibly have an effect on nicotine dependence PMID: 26370685
12. CYP2A6 genetic variation alters striatal-cingulate circuits, network hubs, and executive processing in smokers. Because the CYP2A6 effect was seen only in smokers, these data suggest that the rate of nicotine metabolism-and thus the concentration of nicotine presented to the brain over the course of nicotine addiction-shapes brain circuits that, among other functions, compute reward and impulsivity processes. PMID: 27865452
13. a greater CYP2A6 activity causes smokers to smoke more extensively and be exposed to higher levels of carcinogens, resulting in an increased risk for lung cancer. PMID: 27488534
14. Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype PMID: 27902773
15. study demonstrated a strong dose-dependent association between reduced CYP2A6 activity determined by genotypes and reduced risk of lung cancer PMID: 28182203
16. Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank PMID: 27815364
17. drug and the major metabolites were compared with the kinsenoside-cotreated samples. The effect of kinsenoside was negligible on the enzyme activity of all the CYP isozymes tested even though CYP2A6 was slightly inhibited at higher concentrations. PMID: 27322236
18. CYP2A6 gene variants were associated with markedly reduced nicotine and cotinine clearances. PMID: 27035242
19. CYP2A6 polymorphisms are associated with poor response to chemotherapy in gastric cancer. PMID: 26715117
20. Combined 3D-QSAR and docking procedures yielded precise information about the common and distinct interactions of inhibitors and the enzyme active sites of CYP2A6. PMID: 26648056
21. P450 2A13 is one of the important enzymes that oxidizes polycyclic aromatic hydrocarbons PMID: 26247835
22. It was concluded that, although decreased CYP2A6 AS tended to reduce the risk of bladder cancer in Japanese smokers, no significant association was recognized in this population. PMID: 26725431
23. Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in young smokers. PMID: 25744963
24. Slow nicotine metabolism mediated by CYP2A6 increases risk for tobacco dependence throughout adolescence. PMID: 26644138
25. carcinogen exposure and thereby lower risk of lung cancer. Despite the association between nicotine metabolism (CYP2A6 activity phenotype and diplotypes) and smoking intensity PMID: 26818358
26. lower lung cancer risk observed in CYP2A6 poor metabolizers is partially explained by the strong influence of CYP2A6 genetic polymorphisms on nicotine uptake and metabolism PMID: 26662855
27. phenotypic association studies in population in Nigeria: Data suggest polymorphisms in CYP2A6 exist in the population studied; distribution of CYP2A6 activity is trimodal; influence of age/sex on activity are not significant in this biomarker study. PMID: 26098700
28. No associations were found between the analyzed variants and smoking, however, there was an association among non-smoking subjects between the A allele of rs16969968 and high body mass index. PMID: 26757861
29. Report isolation of CYP2A6 inhibitors from Vernonia cinerea. PMID: 25857233
30. Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. PMID: 26366873
31. CYP2A6 genetic polymorphisms may play important roles in the development of SQCC in Japanese smokers. PMID: 26091970
32. The detected CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in nicotine metabolite ratio (NMR) in these study samples. PMID: 26407342
33. differences in genetic variations and haplotypes of CYP2A6, CYP2B6, CYP2C8, and CYP2E1 were observed among ethnic populations. PMID: 24988984
34. We have for the first time demonstrated that the tumor suppressor protein, p53, is a regulator of the CYP2A6 gene. PMID: 26343999
35. CYP2A7 affects CYP2A6 expression by competing for miR-126* binding. PMID: 25710939
36. meta-analysis suggests that CYP2A6 gene polymorphism is associated with daily cigarette consumption. No association with tobacco dependence was found. PMID: 25683822
37. Nicotine dependence among current smokers homozygous for the SLC6A3 10r allele was lower than that of smokers carrying minor alleles, a CYP2A6 polymorphism might mediate this association. PMID: 25526961
38. Genetic variation in CYP2A6 protein influence smoking behaviors to carbon monoxide level. PMID: 25072098
39. The effects of Smilax root on reactive oxygen species and CYP2A6 expression in Hep G2 cells are reported. PMID: 25220663
40. Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. PMID: 24033696
41. secondhand smoke-exposed pregnant women with CYP2A6*1/*4 or *4/*4 genotype had a significantly lower median cotinine level than women with CYP2A6*1/*1 genotype PMID: 24163286
42. Polymorphisms in CYP2A6 gene is associated with Crohn's disease. PMID: 24651583
43. CYP2A6 is located within genes previously associated with chronic obstructive pulmonary disease susceptibility in smokers. PMID: 25006744
44. Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment. PMID: 24127329
45. Results show that variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk. PMID: 24045616
46. study identified seven novel nonsynonymous variants in a population of African American light smokers; each reduced in-vitro CYP2A6 protein expression, enzymatic activity and/or stability, consistent with the associated slow metabolism phenotype. PMID: 24305170
47. CYP2A6 activity was higher in Swedes compared to Koreans (p<0.0001), even among carriers of rapid genotypes. We report major differences in CYP2A6 enzyme activity between Swedes and Koreans mainly due to CYP2A6 genetic variation but not exclusively. PMID: 22850738
48. CYP2A6 and UGT2B10 genotype explain 53% of the variance in oral nicotine glucuronidation. They are also significantly associated with undeuterated (D0) nicotine glucuronidation in individuals smoking ad libitum. PMID: 24192532
49. Selective chemical inhibitors of CYP2A6 inhibited metronidazole 2-hydroxylation. PMID: 23813797
50. The presence of the CYP2A6 *1/*1 deletion polymorphism might be associated with an increased lung cancer risk, especially for Asians. PMID: 23733493
顯示更多

收起更多
亞細胞定位：

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
蛋白家族：

Cytochrome P450 family
組織特異性：

Liver.
數據庫鏈接：

HGNC: 2610

OMIM: 122720

KEGG: hsa:1548

STRING: 9606.ENSP00000301141

UniGene: Hs.250615